Jill M. Van Dalfsen

Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis

Steven M. Rowe, Sonya L. Heltshe, Tanja Gonska et al. · American Journal of Respiratory and Critical Care Medicine · 2014 · 498 citations

Medicine, Pharmacology, Pharmacotherapy +17

Tobramycin Solution for Inhalation Reduces Sputum <i>Pseudomonas aeruginosa</i> Density in Bronchiectasis

Alan F. Barker, Leslie Couch, Stanley B. Fiel et al. · American Journal of Respiratory and Critical Care Medicine · 2000 · 338 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Effect of Chronic Intermittent Administration of Inhaled Tobramycin on Respiratory Microbial Flora in Patients with Cystic Fibrosis

Jane L. Burns, Jill M. Van Dalfsen, Ribhi M. Shawar et al. · The Journal of Infectious Diseases · 1999 · 289 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist

David P. Nichols, Sarah J. Morgan, M. Skalland et al. · Journal of Clinical Investigation · 2023 · 202 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Rapid screening of natural products for antimycobacterial activity by using luciferase-expressing strains of Mycobacterium bovis BCG and Mycobacterium intracellulare

Ribhi M. Shawar, D J Humble, Jill M. Van Dalfsen et al. · Antimicrobial Agents and Chemotherapy · 1997 · 52 citations · Full text

Life Sciences, Microbiology, Bacteriology +10